EICHORPublic-registry site landscape for NCT07750574, “Phase 2 Study of Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis”, a Myelofibrosis study sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07750574 (registry record) |
| Study title | Phase 2 Study of Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis |
| Official title | A Randomized, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral Flonoltinib Maleate in Patients With JAK Inhibitor Treatment-Naïve or Resistant Myelofibrosis |
| Sponsor | Chengdu Zenitar Biomedical Technology Co., Ltd |
| Condition(s) | Myelofibrosis; Myelofibrosis Due to and Following Polycythemia Vera; Myelofibrosis Transformation in Essential Thrombocythemia; Myelofibrosis With High Molecular Risk Mutations |
| Phase | PHASE2 |
| Listed sites | 0 |
| Intervention(s) | Flonoltinib Maleate orally |
Patient-friendly overview of this study: eichor.com/study/NCT07750574.
Eichor generates a preliminary site-risk snapshot for NCT07750574 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
